CA2692682C - Sap polypeptides useful in the treatment of mucositis - Google Patents

Sap polypeptides useful in the treatment of mucositis Download PDF

Info

Publication number
CA2692682C
CA2692682C CA2692682A CA2692682A CA2692682C CA 2692682 C CA2692682 C CA 2692682C CA 2692682 A CA2692682 A CA 2692682A CA 2692682 A CA2692682 A CA 2692682A CA 2692682 C CA2692682 C CA 2692682C
Authority
CA
Canada
Prior art keywords
mucositis
sap
sap polypeptide
use according
polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2692682A
Other languages
English (en)
French (fr)
Other versions
CA2692682A1 (en
Inventor
David Paul Hesson
Michael Scott Kramer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Promedior Inc
Original Assignee
Promedior Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US12/215,700 external-priority patent/US9884899B2/en
Application filed by Promedior Inc filed Critical Promedior Inc
Publication of CA2692682A1 publication Critical patent/CA2692682A1/en
Application granted granted Critical
Publication of CA2692682C publication Critical patent/CA2692682C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/785—Alveolar surfactant peptides; Pulmonary surfactant peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Saccharide Compounds (AREA)
CA2692682A 2007-07-06 2008-07-07 Sap polypeptides useful in the treatment of mucositis Active CA2692682C (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US95863407P 2007-07-06 2007-07-06
US60/958,634 2007-07-06
US96134307P 2007-07-20 2007-07-20
US60/961,343 2007-07-20
US12/215,700 2008-06-27
US12/215,700 US9884899B2 (en) 2007-07-06 2008-06-27 Methods for treating fibrosis using CRP antagonists
PCT/US2008/008340 WO2009009034A2 (en) 2007-07-06 2008-07-07 Methods and compositions useful in the treatment of mucositis

Publications (2)

Publication Number Publication Date
CA2692682A1 CA2692682A1 (en) 2009-01-15
CA2692682C true CA2692682C (en) 2017-05-02

Family

ID=40076757

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2692682A Active CA2692682C (en) 2007-07-06 2008-07-07 Sap polypeptides useful in the treatment of mucositis

Country Status (9)

Country Link
EP (1) EP2185581B1 (enExample)
JP (1) JP5329538B2 (enExample)
CA (1) CA2692682C (enExample)
DK (1) DK2185581T3 (enExample)
ES (1) ES2554167T3 (enExample)
HU (1) HUE026850T2 (enExample)
PL (1) PL2185581T3 (enExample)
PT (1) PT2185581E (enExample)
WO (1) WO2009009034A2 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5220025B2 (ja) 2006-12-04 2013-06-26 プロメディオール， インコーポレイテッド 線維症疾患を処置するための併用療法
US9884899B2 (en) 2007-07-06 2018-02-06 Promedior, Inc. Methods for treating fibrosis using CRP antagonists
US8497243B2 (en) 2007-07-06 2013-07-30 Promedior, Inc. Methods and compositions useful in the treatment of mucositis
PT2405929T (pt) 2009-03-11 2018-07-23 Promedior Inc Métodos de tratamento para distúrbios autoimunes
PT2405928T (pt) 2009-03-11 2017-02-07 Promedior Inc Métodos de tratamento e de diagnóstico para patologias de hipersensibilidade
UA110323C2 (en) 2009-06-04 2015-12-25 Promedior Inc Derivative of serum amyloid p and their receipt and application
HUE041034T2 (hu) * 2009-06-17 2019-05-28 Promedior Inc SAP-variánsok és alkalmazásuk
RU2020111934A (ru) * 2013-10-08 2020-04-29 Промедиор, Инк. Способы лечения фиброзного рака
EP3669885A1 (en) * 2018-12-20 2020-06-24 Humanitas Mirasole S.p.A. Use of sap for the treatment of eurotiomycetes fungi infections

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992021364A1 (en) * 1991-05-31 1992-12-10 New England Deaconess Hospital Corporation Cea-binding proteins and methods for their isolation and use
GB9317120D0 (en) * 1993-08-17 1993-09-29 Royal Postgrad Med School Human serum amyloid p component
WO1999005394A1 (en) * 1997-07-23 1999-02-04 Cleansorb Limited Methods for deposition of materials in underground reservoirs
AU2006290437A1 (en) * 2005-05-13 2007-03-22 Eisai R&D Management Co., Ltd. Methods of reducing the severity of oral and gastrointestinal mucositis
WO2007047796A2 (en) * 2005-10-17 2007-04-26 Institute For Systems Biology Tissue-and serum-derived glycoproteins and methods of their use
JP5220025B2 (ja) * 2006-12-04 2013-06-26 プロメディオール， インコーポレイテッド 線維症疾患を処置するための併用療法

Also Published As

Publication number Publication date
HUE026850T2 (en) 2016-08-29
JP5329538B2 (ja) 2013-10-30
WO2009009034A3 (en) 2009-02-26
EP2185581B1 (en) 2015-09-02
DK2185581T3 (en) 2015-12-14
EP2185581A2 (en) 2010-05-19
PT2185581E (pt) 2015-12-09
WO2009009034A2 (en) 2009-01-15
AU2008275693A1 (en) 2009-01-15
ES2554167T3 (es) 2015-12-16
CA2692682A1 (en) 2009-01-15
JP2010532787A (ja) 2010-10-14
PL2185581T3 (pl) 2016-01-29

Similar Documents

Publication Publication Date Title
JP5329538B2 (ja) 粘膜炎の治療において有用な方法および組成物
JP6737786B2 (ja) 骨髄異形成症候群および鉄芽球性貧血を処置するための方法
US8497243B2 (en) Methods and compositions useful in the treatment of mucositis
CN106659772B (zh) 在疾病和紊乱的治疗中调节肾酶的组合物和方法
US11571427B2 (en) Targeting the CBM signalosome complex induces regulatory T cells to inflame the tumor microenvironment
JP2017523140A (ja) 潰瘍を処置するための方法および組成物
KR20160023669A (ko) 다양한 질병의 치료를 위한 jnk 신호 전달 경로의 세포 투과성 펩타이드 억제자의 새로운 용도
BR112020024040A2 (pt) Regimes de dosagem de imunoconjugado anti-cd37
CN114630681A (zh) 包含actrii受体拮抗剂的肝疾病或障碍的治疗
Yin Pericyte-derived heme-binding protein 1 promotes angiogenesis and improves erectile function in diabetic mice
ES2878248T3 (es) Compuestos para tratar el bloqueo de la remielinización en enfermedades asociadas con la expresión de la proteína de envoltura HERV-W
CA3001654A1 (en) Uses of myostatin antagonists, combinations containing them and uses thereof
KR20170021349A (ko) 다양한 질병의 치료를 위한 jnk 신호 전달 경로의 세포 투과성 펩타이드 억제자의 새로운 용도
Shu et al. The multi-kinase inhibitor afatinib serves as a novel candidate for the treatment of human uveal melanoma
RS54972B1 (sr) Kombinovana terapija za lečenje raka dojke
US11548942B2 (en) Methods of treating a wasting syndrome, increasing growth hormone levels, and increasing GHSR activity with a LEAP2 antibody
JP7590083B2 (ja) 併用療法
WO2006036729A2 (en) USE OF TGF-β ANTAGONISTS TO LIMIT NEPHROTOXICITY OF IMMUNOSUPPRESSIVE AGENTS
AU2008275693B2 (en) Methods and compositions useful in the treatment of mucositis
WO2022046800A2 (en) Beclin 2 and uses thereof for treating cancer and neurodegenerative diseases
US20250122507A1 (en) Depletion of fndc5 reduces cancer induced muscle loss/cachexia
RU2838150C1 (ru) Лечение заболевания или нарушения со стороны печени, предусматривающее применение антагонистов рецепторов actrii
Bailey Genetic and Pharmaceutical Targeting of HIF-1α Enhances PD-L1 Expression in Normal Tissue while Repressing It in Cancer: An Optimal Strategy for Combination Immunotherapy
CN114980901A (zh) 使用针对浆细胞的抑制剂或细胞毒性剂治疗慢性疲劳综合征的方法
Lee Microglia and macrophages in different types of chronic pain

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20130606

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-4-4-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20251022

H13 Ip right lapsed

Free format text: ST27 STATUS EVENT CODE: N-4-6-H10-H13-H100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE AND LATE FEE NOT PAID BY DEADLINE OF NOTICE

Effective date: 20260218

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260218